Brain tumor awareness is home to a number of different therapies, which goes without saying. It seems as though these particular growths are going to be targeted in the best of ways, specialists being able to assess what can be done in order to help them. This is where the ICT-107 can come into play and it was one that was spoken about in a recent report. From what I have picked up on, it is the kind of report that is more than worth talking about.
There was a written report on Medical News Today that spoke about this condition, which is something that should be gone about in detail. Glioblastoma multiforme seems to be the name of the game, which isn't hard to see why once you understand the details associated with it. After all, this particular type of brain tumor has been viewed as the most common and aggressive in this field. More details can be picked up on by referring to strong organizations such as Voices against Brain Cancer.
From what I have seen, this condition is one in which the cancerous cells seem to regenerate rather quickly. The cells are ones which feed off of the blood stream in the body, which means that there is a source of nourishment set in place. The American Brain Tumor Association went into detail about this as well as the level of risk that was seen. Even though this condition can come about in anyone, it seems as though said risk increases with men more than women, according to the ABTA.
The Cedars-Sinai Medical Group put together a study that would be able to bring the ICT-107 vaccine into use in a big way. The way that this drug would be put to use is that it would tell the immune system about the cancerous cells, which would then lead to a response that could kill the tumor. However, this is not a vaccine that can be administered immediately, as basic surgery is required beforehand. Once this is done, the drug is brought into the body three times a week during two-week intervals.
I think that these particular results were quite positive, as it seems like seven of the sixteen patients that were originally involved could be helped that much more in the long term. Survival rates extended between 60.7 and 82.7 months, which is great for those who consistently bring attention to the matter. In addition, take into account that six of the original patients were said to be "progression-free." They did not have to worry about tumors coming back and the fact that treatment did not have to be followed up on speaks greater volumes.
There was a written report on Medical News Today that spoke about this condition, which is something that should be gone about in detail. Glioblastoma multiforme seems to be the name of the game, which isn't hard to see why once you understand the details associated with it. After all, this particular type of brain tumor has been viewed as the most common and aggressive in this field. More details can be picked up on by referring to strong organizations such as Voices against Brain Cancer.
From what I have seen, this condition is one in which the cancerous cells seem to regenerate rather quickly. The cells are ones which feed off of the blood stream in the body, which means that there is a source of nourishment set in place. The American Brain Tumor Association went into detail about this as well as the level of risk that was seen. Even though this condition can come about in anyone, it seems as though said risk increases with men more than women, according to the ABTA.
The Cedars-Sinai Medical Group put together a study that would be able to bring the ICT-107 vaccine into use in a big way. The way that this drug would be put to use is that it would tell the immune system about the cancerous cells, which would then lead to a response that could kill the tumor. However, this is not a vaccine that can be administered immediately, as basic surgery is required beforehand. Once this is done, the drug is brought into the body three times a week during two-week intervals.
I think that these particular results were quite positive, as it seems like seven of the sixteen patients that were originally involved could be helped that much more in the long term. Survival rates extended between 60.7 and 82.7 months, which is great for those who consistently bring attention to the matter. In addition, take into account that six of the original patients were said to be "progression-free." They did not have to worry about tumors coming back and the fact that treatment did not have to be followed up on speaks greater volumes.
About the Author:
Visit Voices Against Brain Cancer if you are seeking more information about brain tumor awareness and research.
Comments :
0 commentaires to “ICT-107 & Speaking About Brain Tumor Awareness”
Enregistrer un commentaire